^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Eylea (aflibercept intravitreal)

    i
    Other names: BAY86-5321, AVE0005, AVE-0005, VEGF Trap-Eye, AVE 0005, BAY865321, BAY86 5321
    Company:
    Bayer, Regeneron
    Drug class:
    VEGF-A inhibitor, PIGF inhibitor
    Related drugs:
    5d
    EYP-1901-302: A 2-year Study of EYP-1901 in Subjects with Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will Be Determined At Week 52 (clinicaltrials.gov)
    P3, N=400, Recruiting, EyePoint Pharmaceuticals, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eylea (aflibercept intravitreal)
    9d
    QUASAR: A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) (clinicaltrials.gov)
    P3, N=822, Active, not recruiting, Bayer | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    12d
    Comparing Intravitreal Aflibercept Monotherapy Vs Aflibercept Combined with Reduced Fluence PDT in PCV Treatment (clinicaltrials.gov)
    P=N/A, N=60, Completed, Singapore National Eye Centre | Active, not recruiting --> Completed
    Trial completion
    |
    Visudyne (verteporfin) • Eylea (aflibercept intravitreal)
    14d
    A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects with Neovascular Age-Related Macular Degeneration (clinicaltrials.gov)
    P3, N=434, Not yet recruiting, Rophibio, Inc. | Initiation date: Sep 2024 --> Jan 2025
    Trial initiation date
    |
    Eylea (aflibercept intravitreal)
    22d
    Ocular Safety and Usability Study for FYB203 PFS (clinicaltrials.gov)
    P4, N=30, Completed, Formycon AG
    New P4 trial
    |
    Eylea (aflibercept intravitreal)
    22d
    OPHTH-010915: Aflibercept in Recurrent or Persistent CNV (clinicaltrials.gov)
    P=N/A, N=80, Recruiting, Medical University of Vienna | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Sep 2023 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    Eylea (aflibercept intravitreal) • Lucentis (ranibizumab)
    24d
    SPECTRUM-US: An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting (clinicaltrials.gov)
    P=N/A, N=0, Withdrawn, Regeneron Pharmaceuticals | N=800 --> 0 | Initiation date: Aug 2024 --> Dec 2024 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial initiation date • Trial withdrawal • Real-world evidence • Real-world
    |
    Eylea (aflibercept intravitreal)
    24d
    Mean Visual Acuity Changes Following Five Injections of Aflibercept (clinicaltrials.gov)
    P=N/A, N=48, Active, not recruiting, McMaster University | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    Eylea (aflibercept intravitreal)
    28d
    FAN: Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P4, N=70, Active, not recruiting, Medical University of Graz | Trial completion date: Feb 2025 --> Jun 2025 | Trial primary completion date: Oct 2024 --> Mar 2025
    Trial completion date • Trial primary completion date
    |
    VEGFA (Vascular endothelial growth factor A)
    |
    Eylea (aflibercept intravitreal)
    1m
    A Study of IBI302 in Patients With nAMD (clinicaltrials.gov)
    P2, N=231, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    1m
    A 2-year Study of EYP-1901 in Subjects with Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will Be Determined At Week 52 (clinicaltrials.gov)
    P3, N=400, Not yet recruiting, EyePoint Pharmaceuticals, Inc.
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    1m
    DEUTERON: A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P4, N=45, Recruiting, Bayer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eylea (aflibercept intravitreal)
    1m
    PRISM: 4D-150 in Patients with Neovascular (Wet) Age-Related Macular Degeneration (clinicaltrials.gov)
    P1/2, N=215, Recruiting, 4D Molecular Therapeutics | N=150 --> 215 | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2024 --> Nov 2025
    Enrollment change • Trial completion date • Trial primary completion date • Gene therapy
    |
    Eylea (aflibercept intravitreal)
    2ms
    A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO). Primary Efficacy Will be Determined at Week 52. (clinicaltrials.gov)
    P3, N=400, Recruiting, EyePoint Pharmaceuticals, Inc.
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    2ms
    ASCENT: Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD (clinicaltrials.gov)
    P3, N=660, Recruiting, AbbVie | N=465 --> 660 | Trial completion date: Dec 2025 --> Nov 2026 | Trial primary completion date: Feb 2025 --> Nov 2025
    Enrollment change • Trial completion date • Trial primary completion date • Gene therapy
    |
    Eylea (aflibercept intravitreal)
    3ms
    Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE) (clinicaltrials.gov)
    P3, N=413, Completed, Alvotech Swiss AG | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    3ms
    DME HOME: Home- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT (clinicaltrials.gov)
    P=N/A, N=308, Not yet recruiting, Zhongshan Ophthalmic Center, Sun Yat-sen University
    New trial
    |
    Eylea (aflibercept intravitreal)
    3ms
    Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE) (clinicaltrials.gov)
    P2, N=52, Active, not recruiting, Unity Biotechnology, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    3ms
    DEUTERON: A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P4, N=45, Not yet recruiting, Bayer
    New P4 trial
    |
    Eylea (aflibercept intravitreal)
    3ms
    VERONA: Study of EYP-1901 in Patients With Diabetic Macular Edema (DME) (clinicaltrials.gov)
    P2, N=25, Recruiting, EyePoint Pharmaceuticals, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eylea (aflibercept intravitreal) • Fumena (vorolanib)
    3ms
    Comparison of the Efficacy of Conbercept and Aflibercept in Different Treatment Regimens for Exudative Age-related Macular Degeneration (ChiCTR2400087042)
    P4, N=140, Completed, The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University
    New P4 trial
    |
    Eylea (aflibercept intravitreal)
    3ms
    PULSAR: Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye (clinicaltrials.gov)
    P3, N=1011, Completed, Bayer | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    4ms
    DAVIO2: Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (clinicaltrials.gov)
    P2, N=160, Completed, EyePoint Pharmaceuticals, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    4ms
    A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK (clinicaltrials.gov)
    P3, N=675, Recruiting, Kodiak Sciences Inc
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    4ms
    Tejas: Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Ashvattha Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    4ms
    TELeMAC: Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1 (clinicaltrials.gov)
    P3, N=46, Recruiting, Centre Hospitalier Universitaire Dijon | Trial completion date: Jan 2025 --> Dec 2027 | Trial primary completion date: Jan 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Eylea (aflibercept intravitreal)
    4ms
    Tejas: Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME (clinicaltrials.gov)
    P2, N=50, Recruiting, Ashvattha Therapeutics, Inc. | N=30 --> 50 | Trial completion date: Jun 2023 --> Dec 2024 | Trial primary completion date: May 2023 --> Nov 2024
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Eylea (aflibercept intravitreal)
    4ms
    ELARA: A Single-Arm Study of Aflibercept 8 mg Dosed in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) (clinicaltrials.gov)
    P3, N=400, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eylea (aflibercept intravitreal)
    5ms
    PHOTON: Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease (clinicaltrials.gov)
    P2/3, N=660, Completed, Regeneron Pharmaceuticals | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    5ms
    Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration (clinicaltrials.gov)
    P3, N=825, Recruiting, Ocular Therapeutix, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eylea (aflibercept intravitreal)
    5ms
    DAZZLE: A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration. (clinicaltrials.gov)
    P2/3, N=559, Terminated, Kodiak Sciences Inc | Phase classification: P2b --> P2/3
    Phase classification
    |
    Eylea (aflibercept intravitreal)
    5ms
    Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration (clinicaltrials.gov)
    P3, N=825, Not yet recruiting, Ocular Therapeutix, Inc.
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    5ms
    CLN-0046: Treatment of AMD Subjects With OTX-TKI (clinicaltrials.gov)
    P1, N=29, Completed, Ocular Therapeutix, Inc. | Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Jan 2024 | Trial primary completion date: Dec 2022 --> Jan 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • Eylea (aflibercept intravitreal) • Lucentis (ranibizumab)
    5ms
    ELARA: A Single-Arm Study of Aflibercept 8 mg Dosed in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) (clinicaltrials.gov)
    P3, N=400, Not yet recruiting, Regeneron Pharmaceuticals
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    6ms
    A Study of Longer Interval of IVT IBI302 in Subjects With nAMD (clinicaltrials.gov)
    P2, N=132, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruiting --> Completed | Trial primary completion date: Feb 2024 --> May 2024
    Trial completion • Trial primary completion date
    |
    Eylea (aflibercept intravitreal)
    6ms
    Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS) (clinicaltrials.gov)
    P3, N=35, Completed, Regeneron Pharmaceuticals | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    6ms
    PHOTONiC: A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema (clinicaltrials.gov)
    P3, N=322, Recruiting, Bayer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eylea (aflibercept intravitreal)
    6ms
    PRECISION: Comparative Study of Dexamethasone Implant to Intravitreal Aflibercept in Subjects With Diabetic Macular Edema (clinicaltrials.gov)
    P4, N=23, Completed, The Cleveland Clinic | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    7ms
    Changes in Inflammatory Biomarkers Including Soluble CD14 and Hyperreflective Foci in DME Patients Treated With Aflibercept (FORESIGHT) (clinicaltrials.gov)
    P4, N=23, Completed, Hyewon Chung | Unknown status --> Completed | N=47 --> 23 | Trial completion date: Sep 2022 --> Feb 2024
    Trial completion • Enrollment change • Trial completion date
    |
    Eylea (aflibercept intravitreal)
    7ms
    Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE) (clinicaltrials.gov)
    P3, N=413, Active, not recruiting, Alvotech Swiss AG | Trial completion date: Jan 2025 --> Oct 2024
    Trial completion date
    |
    Eylea (aflibercept intravitreal)
    7ms
    A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy (clinicaltrials.gov)
    P2, N=178, Recruiting, Boehringer Ingelheim | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eylea (aflibercept intravitreal)
    7ms
    PHOTONiC: A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema (clinicaltrials.gov)
    P3, N=322, Not yet recruiting, Bayer
    New P3 trial
    |
    Eylea (aflibercept intravitreal)